Study Findings on Breast Cancer Discussed by Researchers at China Pharmaceutical University (Confirming the efficacy and safety of CDK4/6 inhibitors in the first-line treatment of HR+ advanced breast cancer: a systematic review and meta-analysis).

A recent study conducted by researchers at China Pharmaceutical University evaluated the efficacy and safety of cyclin-dependent kinase (CDK) 4/6 inhibitors in the first-line treatment of hormone receptor-positive (HR+) advanced breast cancer. The study analyzed survival data using fractional polynomial modeling methods and found that CDK4/6 inhibitors, including abemaciclib, palbociclib, and ribociclib, significantly improved survival in treatment-naive patients. However, the use of these inhibitors also increased the risk of adverse events, particularly with palbociclib. The study suggests that abemaciclib and ribociclib may be the best options for prolonging progression-free survival and overall survival, respectively. [Extracted from the article]